Pulmonary Hypertension
Conditions
Keywords
pulmonary hypertension, impedancemetry, cardiac output
Brief summary
Monocentric cohort study, prospective, evaluating the variability of cardiac output measurement by resting and stress impedancemetry as a prognostic factor for Pulmonary Hypertension
Detailed description
Cardiac impedancemetry is a technique that allows an electrical representation of cardiac flows. To do this, 6 electrodes are applied to the thorax and a low intensity and high frequency electrical current is transmitted. The impedance is recorded and the variations of the impedance represent the changes in intra-thoracic volume and thus the volume of systolic ejection. This measurement can be done at rest but also during exercise during the walking test. A test of the NO / CO coupled transfer measurement is also performed. The devices that will be used in this project are the Physio-Flow® system and Masterscreen NO / CO coupled transfer measurement device
Interventions
DEVICEcardiac impedancemetry
The cardiac output is measured by impedance measurement at rest and during the walking test.
Sponsors
University Hospital, Toulouse
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patient over 18 years and under 80 years * Patients who have been diagnosed with PAH (group 1 PH according to the Nice 2013 classification) or post-embolic pulmonary hypertension (group 4 PH) under medical treatment; * HTP incident or prevalent less than 6 months * Patient coming for follow-up or emergency consultation or hospitalization with a clinical examination and a walking test * Patient affiliated to a health insurance scheme * Patient having signed informed consent
Exclusion criteria
* Subjects under juridical protections or tutelage measure * pregnant or lactating woman * pulmonary hypertension du to cardiac pathology, chronic respiratory disease, or uncertain determinism. * pulmonary hypertension of group 4 treated surgically or endoscopically. * pulmonary hypertension incident or prevail for 6 months or more * contraindication to impedancemetry * inability to perform a walking test
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Measure of cardiac flow variation at 0 month by impedancemetry | 0 month | The variation of cardiac flow is measured by impedancemetry at rest |
| Measure of cardiac flow variation at 6 month by impedancemetry | 6 month | The variation of cardiac flow is measured by impedancemetry at rest |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Measure of cardiac flow variation during walking test | 0 month | The variation of cardiac flow is measured by impedancemetry during walking test |
| Measure of cardiac flow variation during walking test at 6 month | 6 month | The variation of cardiac flow is measured by impedancemetry during walking test |
| Correlation between measurement of capillary blood volume and measurement of cardiac flow | 0 month | Evaluate the correlation between measurement of capillary blood volume and measurement of cardiac flow by impedancemetry |
| Occurrence of an undesirable event | 18 month | Collection of undesirable event like : - Deaths (all causes combined), Hospitalization for aggravation of PAH, Progression of the disease or decrease, Unsatisfactory long-term clinical response |
Countries
France
Outcome results
None listed